Relistor reduces mortality in patients with opioid-induced constipation
In this exclusive video, Lynn R. Webster, MD, from PRA Health Sciences in Salt Lake City, discusses his study from Digestive Disease Week that explored the impact of Relistor, a mu-opioid receptor agonist, on all-cause mortality in patients with opioid-induced constipation.
In a retrospective analysis of 11 phase 2 and 3 randomized controlled trials, researchers found that the drug (methylnaltrexone, Salix) did reduce mortality and observed significant reductions in mortality among patients with cancer.
Webster LR, et al. Abstract 8. Presented at: Digestive Disease Week; May 2-5, 2020; Chicago (meeting canceled).
Disclosures: Webster reports consulting or advising for Bonti, BDSI, Charleston Labs, Daiichi Sankyo, Ensyse Biosciences, Elsyium Therapeutics, Insys Therapeutics, Mallinckrodt Pharmaceuticals, Merck, Neurana, Pain Therapeutics, Pernix, Pfizer, Salix, Shionogi, Teva, and Trevena.